Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,231.94 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗
IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns. 
Via The Motley Fool
Topics ETFs
News headline image
Which is the Better Choice for Healthcare Investors? IYH or BBH? ↗
BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield. 
Via The Motley Fool
Topics ETFs
News headline image
Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It? ↗
One small investment offers big benefits for Nvidia. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026 ↗
This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends. 
Via The Motley Fool
News headline image
Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗
There are good reasons to invest in Lilly and to hold off. 
Via The Motley Fool
News headline image
History Says Doing This 1 Thing Will Score You an Investing Win -- Even After a Market Crash. ↗
It's something very simple. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
News headline image
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? ↗
So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off. 
Via The Motley Fool
News headline image
IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? ↗
Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years. 
Via The Motley Fool
Topics ETFs
News headline image
Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock. ↗
Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating. 
Via The Motley Fool
News headline image
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026? ↗
PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost. 
Via The Motley Fool
Topics ETFs
News headline image
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? ↗
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential. 
Via The Motley Fool
Topics ETFs
News headline image
1 Unpopular Stock That Should Get More Attention and 2 That Underwhelm
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
My Forever Portfolio: 5 Undervalued Stocks to Buy Now and Hold Forever ↗
Investing for the long-term requires a different strategy. 
Via The Motley Fool
News headline image
Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026? ↗
PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost. 
Via The Motley Fool
Topics ETFs
News headline image
Is It Too Late to Buy Eli Lilly? ↗
The stock has soared 400% in recent years. 
Via The Motley Fool
News headline image
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger ↗
As Middle East tensions resurface and futures drop, VIG, VIGI, and FDVV offer dividend growth ETFs combining income with exposure to technology and global equities. 
Via MarketBeat
Topics Artificial Intelligence ETFs Stocks
News headline image
Stocks making big moves yesterday: Carlisle, Rivian, Blink Charging, Genpact, and Eli Lilly
Check out the companies making headlines yesterday: Carlisle (NYSE:CSL): Building envelope solutions provider Carlisle Companies (NYSE:CSL) fell by 4.2% on T... 
Via StockStory
Topics Economy Electric Vehicles
News headline image
Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026 ↗
Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them. 
Via The Motley Fool
News headline image
Why Eli Lilly Stock Climbed to a Record High Today ↗
Wall Street is getting more bullish on the pharma giant's shares. 
Via The Motley Fool
News headline image
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom ↗
Don't sleep on these medical device leaders. 
Via The Motley Fool
Topics Supply Chain
News headline image
3 Reasons to Buy Novo Nordisk Stock ↗
The stock is down, but it isn't out yet. 
Via The Motley Fool
News headline image
Why Eli Lilly (LLY) Stock Is Trading Up Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his pri... 
Via StockStory
News headline image
U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend ↗
Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks. 
Via The Motley Fool
News headline image
Warren Buffett Has Recommended 1 Investment for Decades -- but There's a Hidden Risk Many Investors Are Overlooking ↗
This key factor didn't exist when Buffett first gave the advice, but does that change its appeal? 
Via The Motley Fool
Topics Artificial Intelligence ETFs Economy
News headline image
Eli Lilly's Market Cap Balloons Again On This IPO's Setback ↗
Eli Lilly shares hit a new record high Tuesday after IPO stock Kailera posted lackluster test results for its obesity drug. 
Via Investor's Business Daily
Topics Initial Public Offering
News headline image
Eli Lilly Stock Hits a New All-Time High: Has It Gotten Too Expensive to Buy? ↗
Shares of Eli Lilly have risen by over 40% since the company last reported earnings. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Eli Lilly Stock? Here's What $1,000 Invested Today Could Be Worth in 10 Years. ↗
The stock has surged 160% over the past three years. Meanwhile, two key drugs could continue driving rampant growth. 
Via The Motley Fool
News headline image
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner ↗
Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near. 
Via MarketBeat
News headline image
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026? ↗
Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion. 
Via The Motley Fool
News headline image
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? ↗
The weight-loss market is crowded, but this company's lead drug candidate has several key advantages. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.